PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Side effects of hormonal therapy in prostate cancer
Article published in Urologia Polska 2006/59/1.

authors

Mmc Van Den Heijkant, Jjmch De La Rosette, Tm De Reijke
Academic Medical Centre, Department of Urology, Amsterdam

keywords

prostate cancer, hormonal therapy, side effects

summary

Hormonal therapy is the first therapeutic choice for patients presenting with metastatic prostate cancer. Combined external beam radiotherapy and hormonal therapy has been shown to improve survival for patients with a locally advanced prostate cancer. Intervention on the hypothalamic-pituitary-testicular axis is possible on different levels but depending on the site of interaction different side effects can be induced. Knowledge of this hormonal axis is essential to understand the side effect profile of the different hormonal manipulations for prostate cancer. This overview covers the different hormonal manipulations and the induced side effects.

references

  1. 1. Visser O, Coebergh JWW, Dijck JAAM: Incidence of cancer in the Netherlands 1998. Utrecht: Vereniging van Integrale Kankercentra, 2002.
  2. 2. Wilt T, Nair B, Mac Donald R, Rutks I: Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Review 2003; issue 3.
  3. 3. Smaletz O, Scherr HI, Small EJ et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002, 20, 3972-3982.
  4. 4. Bolla M, Collette L, Blank L et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360, 103-106.
  5. 5. Huggins C, Hodges CV: Studies on prostatic cancer. I. The effects of castration of estrogen and of androgen injection on serum phosphatases in metastati carcinoma of the prostate. Cancer Res 1941, 1, 293-297.
  6. 6. Radlmaier A, Bormacher K, Neumann F: Hot flushes: mechanism and prevention. EORTC Genitourinary Group 1990; monograph 8, Treatment of prostatic cancer-facts and controversies: 131-40.
  7. 7. Higano CS: Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003, 61 (suppl 2a), 32-38.
  8. 8. Smith MR: Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003, 97 (suppl 3), 789-795.
  9. 9. Ross RW, Small EJ: Osteoporosis in men with androgen deprivation therapy for prostate cancer. J Urol 2002,167, 1952-1916.
  10. 10. Potosky AL, Knopf K, Clegg LX et al: Qualith of life outcomes after primary androgen deprivation therapy; results from the prostate cancer outcomes study. J Clin Oncol 2001, 19, 3750-3757.
  11. 11. Trachtenberg J, Gittleman M, Steidle C et al: A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002, 167, 1670-1674.
  12. 12. Landstrom M, Damber JE, Bergh A: Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma. Prostate 1994, 25, 10-18.
  13. 13. Hedlund PO, Ala-Opas M, Brekkan E et al: Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer – Scandinavian Prostatic Cancer group (SPCG) Study no. 5. Scand Urol Nephrol 2002, 36, 405-413.
  14. 14. Ockrim JL, Lalani EN, Laniado ME et al: Transdermal estradiol therapy for advanced prostate cancer-forward to the past? J Urol 2003, 169, 1735-1737.
  15. 15. Bae DC, Stein BS: The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate. J Urol 2004, 172, 2137-2144.
  16. 16. Oefelein MG, Resnick MI: The impact of osteoporosis in men treated for prostate cancer. Urol Clin North Am 2004, 31, 313-319.
  17. 17. Scherr DS, Pitts WR: The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003, 170, 1703-1708.
  18. 18. Mc Leod DG, Iversen P: Gynecomastia with prostate cancer: a review of treatment options. Urol 2000, 56, 713-720.
  19. 19. Pound CR, Partin AW, Eisenberger MA et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281, 1591-1597.

correspondence

Th. M. de Reijke
Academic Medical Centre
Department of Urology
Meibergdreef 9
1105 AZ Amsterdam
tel. (0031) 20 5666 60 04
t.m.dereyke@amc.uva.nl